MA39533A1 - Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives - Google Patents

Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives

Info

Publication number
MA39533A1
MA39533A1 MA39533A MA39533A MA39533A1 MA 39533 A1 MA39533 A1 MA 39533A1 MA 39533 A MA39533 A MA 39533A MA 39533 A MA39533 A MA 39533A MA 39533 A1 MA39533 A1 MA 39533A1
Authority
MA
Morocco
Prior art keywords
compounds
treatment
pharmaceutical composition
neurodegenerative diseases
solvates
Prior art date
Application number
MA39533A
Other languages
English (en)
Other versions
MA39533B1 (fr
Inventor
Patricia Melnyk
Patrick Vermersch
Pascal Carato
Bénédicte Oxombre-Vanteghem
Hélène Zephir
Marion Donnier-Marechal
Original Assignee
Univ Lille Ii Droit & Sante
Centre Hospitalier Regional Et Univ De Lille (Chru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Lille Ii Droit & Sante, Centre Hospitalier Regional Et Univ De Lille (Chru) filed Critical Univ Lille Ii Droit & Sante
Publication of MA39533A1 publication Critical patent/MA39533A1/fr
Publication of MA39533B1 publication Critical patent/MA39533B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/50—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés de formule (i), des sels ou des solvates pharmaceutiquement acceptables de ceux-ci, et leur utilisation.
MA39533A 2014-06-16 2015-06-15 Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives MA39533B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305919 2014-06-16
PCT/EP2015/063370 WO2015193255A1 (fr) 2014-06-16 2015-06-15 Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives

Publications (2)

Publication Number Publication Date
MA39533A1 true MA39533A1 (fr) 2017-09-29
MA39533B1 MA39533B1 (fr) 2018-11-30

Family

ID=50982878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39533A MA39533B1 (fr) 2014-06-16 2015-06-15 Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives

Country Status (29)

Country Link
US (3) US10179761B2 (fr)
EP (1) EP3154934B1 (fr)
JP (1) JP6704355B2 (fr)
KR (1) KR20170041662A (fr)
CN (1) CN106795100B (fr)
AU (1) AU2015276256B2 (fr)
BR (1) BR112016029571A2 (fr)
CA (1) CA2951438C (fr)
CL (1) CL2016003230A1 (fr)
CO (1) CO2017000211A2 (fr)
CR (1) CR20160581A (fr)
DO (1) DOP2016000325A (fr)
EA (1) EA031123B1 (fr)
EC (1) ECSP16094286A (fr)
ES (1) ES2880313T3 (fr)
GT (1) GT201600255A (fr)
IL (1) IL249440B (fr)
MA (1) MA39533B1 (fr)
MX (1) MX2016016769A (fr)
MY (1) MY183757A (fr)
PE (2) PE20170518A1 (fr)
PH (1) PH12016502480A1 (fr)
PL (1) PL3154934T4 (fr)
PT (1) PT3154934T (fr)
SG (1) SG11201610478YA (fr)
TN (1) TN2016000550A1 (fr)
UA (1) UA123041C2 (fr)
WO (1) WO2015193255A1 (fr)
ZA (1) ZA201608558B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
WO2024033399A1 (fr) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Ligand sigmar1 pour traitement du cancer du pancréas

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2241498A (en) * 1940-11-25 1941-05-13 Champ Items Inc Method of manufacturing oil shields for internal combustion engines
US2441498A (en) * 1943-07-15 1948-05-11 Astra Apotekarnes Kem Fab Alkyl glycinanilides
GB1307250A (en) * 1970-06-16 1973-02-14 May & Baker Ltd Benzene derivatives
DE2438288A1 (de) * 1974-08-09 1976-02-19 Knoll Ag Neue antiarrhythmika
US4448776A (en) * 1981-02-12 1984-05-15 Karl Bucher Method of using certain substituted aliphatic secondary amines or their salts for easing breathing
JPH02138162A (ja) * 1988-11-19 1990-05-28 Mitsubishi Kasei Corp Ｎ−フェニルアルキル置換−β−アミノ酸アミド誘導体
AU2159692A (en) * 1991-06-06 1993-01-12 G.D. Searle & Co. N-(arylethyl)-n-alkyl-2-(1-pyrrolidinyl)ethylamine derivatives for cns disorders
JPH07188139A (ja) * 1993-12-24 1995-07-25 Kirin Brewery Co Ltd アミド化合物
FR2729146A1 (fr) * 1995-01-06 1996-07-12 Smithkline Beecham Lab Nouveaux derives d'amine, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
JP4629657B2 (ja) * 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
JP2008524139A (ja) 2004-12-15 2008-07-10 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト メタ置換チアゾリノン類、それらの製造及び医薬としての使用
EP2234615A1 (fr) * 2007-12-19 2010-10-06 Wyeth LLC 4-imidazolidinones utilisés comme inhibiteurs des canaux potassiques kv1.5
US9518044B2 (en) * 2011-06-20 2016-12-13 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
US20130274233A1 (en) 2012-04-03 2013-10-17 President And Fellow Of Harvard College Modulators of hedgehog signaling pathway

Also Published As

Publication number Publication date
CA2951438C (fr) 2022-11-29
ES2880313T3 (es) 2021-11-24
IL249440B (en) 2018-07-31
MY183757A (en) 2021-03-11
US10844008B2 (en) 2020-11-24
WO2015193255A1 (fr) 2015-12-23
PL3154934T3 (pl) 2022-02-21
US20210040034A1 (en) 2021-02-11
ZA201608558B (en) 2018-05-30
CR20160581A (es) 2017-04-04
UA123041C2 (uk) 2021-02-10
CO2017000211A2 (es) 2017-04-10
EP3154934B1 (fr) 2021-04-14
EA201790020A1 (ru) 2017-06-30
CA2951438A1 (fr) 2015-12-23
CN106795100B (zh) 2019-11-19
EA031123B1 (ru) 2018-11-30
GT201600255A (es) 2019-09-20
MA39533B1 (fr) 2018-11-30
SG11201610478YA (en) 2017-01-27
CN106795100A (zh) 2017-05-31
JP2017521392A (ja) 2017-08-03
PE20170518A1 (es) 2017-04-30
BR112016029571A2 (pt) 2017-08-22
PL3154934T4 (pl) 2022-02-21
MX2016016769A (es) 2017-08-10
JP6704355B2 (ja) 2020-06-03
PH12016502480A1 (en) 2017-04-10
PT3154934T (pt) 2021-07-19
ECSP16094286A (es) 2019-07-31
AU2015276256A1 (en) 2016-12-22
TN2016000550A1 (en) 2018-04-04
DOP2016000325A (es) 2017-03-15
IL249440A0 (en) 2017-02-28
EP3154934A1 (fr) 2017-04-19
AU2015276256B2 (en) 2019-08-15
PE20181053A1 (es) 2018-07-03
US20170107174A1 (en) 2017-04-20
US20190092721A1 (en) 2019-03-28
CL2016003230A1 (es) 2017-09-08
KR20170041662A (ko) 2017-04-17
US10179761B2 (en) 2019-01-15

Similar Documents

Publication Publication Date Title
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
SA518391624B1 (ar) Ror- منظمات جاما
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201792047A1 (ru) Новые соединения
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201590066A1 (ru) Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
PH12017501668A1 (en) Bace1 inhibitors
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.
EA201790795A1 (ru) СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА
EA202190578A1 (ru) ИНГИБИТОРЫ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ KEAP1-Nrf2
EA201990074A1 (ru) Гетероциклические соединения как иммуномодуляторы